About OncoSynergy
OncoSynergy is a company based in San Francisco (United States) founded in 2011 was acquired by DanDrit in April 2016. OncoSynergy has raised $33.32 million across 8 funding rounds from investors including HHS, National Cancer Institute and KICC. The company has 3 employees. OncoSynergy offers products and services including OS2966 and Therapeutic Platforms. OncoSynergy operates in a competitive market with competitors including Harbour BioMed, Xilio Therapeutics, Zymeworks, Lassen Therapeutics and Ambrx, among others.
Products & Services of OncoSynergy
OncoSynergy offers a comprehensive portfolio of products and services, including OS2966 and Therapeutic Platforms.
Antibody that blocks receptors to inhibit cancer growth and resistance
Platforms for developing treatments against various solid and hematological cancers
Funding Insights of OncoSynergy
OncoSynergy has successfully raised a total of $33.32M across 8 strategic funding rounds. The most recent funding activity was a Series A round of $6.61 million completed in May 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $33.32M
- Total Rounds 8
- Last Round Series A — $6.61M
- First Round $20.01M
(May 2018)
- Investors Count 5
All 8 funding rounds of OncoSynergy with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2026 | $6.61M | Series A | – | – | – |
| May 2022 | $3.45M | Series A | – | – | – |
| Nov 2020 | $250,000 | Debt – Conventional | – | – | – |
| Sep 2020 | $3.25M | Series A | – | – | – |
| Jan 2020 | $300,000 | Grant | – | – | |
| Sep 2019 | $367,772 | Grant | – | – | |
| Sep 2019 | $198,014 | Grant | – | – | |
| May 2018 | $20.01M | Series A | – | Connecticut Innovations |
6 investors in total: 6 institutional.
Investors in OncoSynergy
OncoSynergy has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, National Cancer Institute and KICC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital services for biotech, IT, and innovative sectors in Connecticut. | – | ctinnovations.com | - | |
- | – | navation.com | - | |
Cancer research is conducted and supported by the institute. | – | cancer.gov | Bethesda, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Provider of POS solutions for retailers | 1986 | kicc.co.kr | Seoul, South Korea | |
Develops a dendritic cell vaccine for treating colorectal and non-small-cell lung cancer. | 2001 | dandrit.com | Copenhagen, Denmark |
Investor details for OncoSynergy
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of OncoSynergy
3 people are tracked at OncoSynergy (3 in leadership); the tracked headcount is 3.
| Name | Role | Group |
|---|---|---|
Gregory Wilson | Consulting CFO | Leadership |
Ambar Picon | VP of Corporate & Clinical Operations | Leadership |
Anne-Marie Carbonell | Founder, CEO & Chief Medical Officer | Leadership |
Complete people profiles for OncoSynergy
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of OncoSynergy
4 dated milestones of OncoSynergy across 15 years, from founding to its latest funding, stage changes and deals.
- Founded OncoSynergy is founded.
- Exit Acquired by DanDrit.
- Funding First funding round of $20.0M.
- Funding Latest funding round, Series A, of $6.6M.
Competitors of OncoSynergy
OncoSynergy operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Harbour BioMed, Xilio Therapeutics, Zymeworks, Lassen Therapeutics and Ambrx, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| harbourbiomed.com | 2016 | Shanghai, China | $312.8M | – | Antibody therapeutics are developed for immunology and oncology diseases. | |
| xiliotx.com | 2016 | Waltham, United States | $233M | 72 | Tumor-selective immunotherapies for cancer treatment are developed. | |
| zymeworks.com | 2003 | Vancouver, Canada | $145.97M | 277 | Bi-specific antibodies and antibody-drug conjugates are developed for cancer treatment. | |
| lassentherapeutics.com | 2019 | San Diego, United States | $116M | 6 | Biotherapeutics targeting cancer via interleukin-11 are developed. | |
| ambrx.com | 2003 | San Diego, United States | $345.9M | 79 | Antibody-drug conjugates are developed for cancers and metabolic disorders. | |
| atreca.com | 2010 | San Carlos, United States | $224.4M | 134 | Antibody therapeutics for anti-cancer immune responses are developed. | |
| bioatla.com | 2007 | San Diego, United States | $162.31M | 41 | Immunotherapies for cancer are developed using conditionally active biologics platform. | |
| leaptx.com | 2011 | Cambridge, United States | $24.68M | 44 | Novel immuno-oncology therapeutics are acquired and developed for clinical advancement. |
Detailed competitors of OncoSynergy
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oncosynergy
Complete news archive for OncoSynergy
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to OncoSynergy
10 companies that operate in the same segment as OncoSynergy (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about OncoSynergy
OncoSynergy was founded in 2011 and raised its 1st funding round 7 years after it was founded.
OncoSynergy is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
OncoSynergy is a funded company, having raised a total of $33.32M across 8 funding rounds to date. The company's 1st funding round was a Series A of $20.01M, raised on May 2018.
OncoSynergy has 3 employees.
OncoSynergy was founded in 2011 and is based in San Francisco, United States. Inhibitors targeting resistance mechanisms in cancer are developed by the company within the oncology sector. Multiple hallmarks of cancer progression are addressed, with efficacy shown in monotherapy and combinations. The lead program, OS2966, consists of a therapeutic antibody that blocks a cell surface receptor, aimed at treating glioblastoma, ovarian cancer, pancreatic cancer, and malignant meningioma.
OncoSynergy's top competitors include Xilio Therapeutics, Ambrx and Harbour BioMed.
OncoSynergy offers OS2966 and Therapeutic Platforms.
OncoSynergy has 6 investors. Key investors include HHS, National Cancer Institute, KICC, Connecticut Innovations, and Navation.
OncoSynergy operates through Oncosynergy, Inc..
Yes. OncoSynergy was acquired by DanDrit in April 2016.